Sight Sciences, Inc. (NASDAQ:SGHT) CTO Sells $10,950.72 in Stock

Sight Sciences, Inc. (NASDAQ:SGHT) CTO David Badawi sold 3,111 shares of the business’s stock in a transaction dated Friday, January 3rd. The stock was sold at an average price of $3.52, for a total transaction of $10,950.72. Following the completion of the sale, the chief technology officer now owns 1,753,370 shares in the company, valued at approximately $6,171,862.40. This trade represents a 0.18 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Sight Sciences Stock Down 2.6 %

NASDAQ:SGHT opened at $3.31 on Wednesday. The company has a market cap of $168.00 million, a price-to-earnings ratio of -3.25 and a beta of 2.57. Sight Sciences, Inc. has a twelve month low of $3.29 and a twelve month high of $8.45. The company has a current ratio of 10.18, a quick ratio of 9.74 and a debt-to-equity ratio of 0.36. The stock has a fifty day simple moving average of $3.93 and a 200-day simple moving average of $5.58.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. The company had revenue of $20.16 million during the quarter, compared to analyst estimates of $20.41 million. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. Analysts anticipate that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on SGHT shares. UBS Group began coverage on Sight Sciences in a research note on Friday, December 6th. They set a “buy” rating and a $5.50 price objective on the stock. Morgan Stanley decreased their price target on Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Monday, November 11th. Citigroup lowered their price target on Sight Sciences from $5.80 to $4.60 and set a “neutral” rating for the company in a research report on Wednesday, December 11th. Lake Street Capital downgraded shares of Sight Sciences from a “buy” rating to a “hold” rating and reduced their target price for the company from $10.00 to $5.00 in a research note on Monday, November 4th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research note on Friday, November 8th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, Sight Sciences has an average rating of “Hold” and an average price target of $5.12.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in Sight Sciences by 335.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 69,660 shares of the company’s stock valued at $439,000 after purchasing an additional 53,658 shares in the last quarter. B. Riley Wealth Advisors Inc. increased its stake in shares of Sight Sciences by 5.4% during the third quarter. B. Riley Wealth Advisors Inc. now owns 195,082 shares of the company’s stock valued at $1,174,000 after buying an additional 10,000 shares during the period. Barclays PLC raised its holdings in shares of Sight Sciences by 317.4% in the third quarter. Barclays PLC now owns 50,300 shares of the company’s stock valued at $317,000 after acquiring an additional 38,248 shares in the last quarter. Geode Capital Management LLC lifted its stake in Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock worth $4,941,000 after acquiring an additional 12,709 shares during the period. Finally, State Street Corp grew its holdings in Sight Sciences by 17.4% during the 3rd quarter. State Street Corp now owns 646,776 shares of the company’s stock worth $4,075,000 after acquiring an additional 95,843 shares in the last quarter. Institutional investors own 55.51% of the company’s stock.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.